4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Aug. 15, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -11.36% and -98.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
4dMT Revenue Jumps 200 Percent in Q2
4d Molecular Therapeutics ( NASDAQ:FDMT ) , a clinical-stage genetic medicines company specializing in targeted gene therapies, reported financial results for the second quarter of fiscal 2025 on August 11, 2025. The headline news was a dramatic revenue surge, with the company delivering $15.0 ...
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to ...
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4D-150 showed +9.7 letter BCVA gain and 78% fewer injections vs. standard aflibercept in DME. No intraocular inflammation or serious adverse events reported through 60 weeks. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Apple ( NASDAQ:AAPL ) , Bloom Energy ( NYSE:BE )
Shares of Apple Inc. AAPL rose in pre-market trading as the company posted stronger-than-expected third-quarter results. The iPhone maker reported fiscal third-quarter revenue of $94 billion, beating analyst estimates of $89.04 billion by 5.6%.
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
EMERYVILLE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to ...
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., July 11, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with focused pipeline shift, as announced in January 2025
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - Vivani Medical ( NASDAQ:VANI )
ALAMEDA, Calif., June 11, 2025 ( GLOBE NEWSWIRE ) -- Vivani Medical, Inc. VANI ( "Vivani" or the "Company" ) , a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer.
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., May 16, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -2.38% and 98.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., May 05, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., May 05, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for ...
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
EMERYVILLE, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., April 11, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in Upcoming Investor Conferences - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., March 27, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to ...
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., Feb. 28, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented ...
4DMT to Participate in Upcoming Investor Conferences - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) , a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in ...
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate ...
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4D-150 reduced injection burden by 83% in a subgroup, with 57% remaining injection-free over 52 weeks. BCVA improved by +2.2 letters. In newly diagnosed patients, 87% needed 0-1 injections, and 80% were injection-free. Injection burden dropped by 94% over 52 weeks.
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program - 4D Molecular Therapeutics ( NASDAQ:FDMT )
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeks
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
EMERYVILLE, Calif., Feb. 08, 2025 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT. 4DMT or the Company ) , a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 52-week ...
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path - 4D Molecular Therapeutics ( NASDAQ:FDMT )
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of CST of -194 µm from ...
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday - Archer Aviation ( NYSE:ACHR ) , Amazon.com ( NASDAQ:AMZN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird raised the price target for Tesla, Inc. TSLA from $280 to $480.
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q3 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -17.91% and 99.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ARS Pharmaceuticals, Inc. ( SPRY ) Reports Q3 Loss, Misses Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -11.11% and 8.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics ( HRTX ) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0% and 9.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics ( NKTR ) Reports Q3 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix ( OCUL ) Moves 6.1% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4D Molecular Therapeutics ( FDMT ) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4D Molecular Therapeutics (FDMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in ...
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster presentation ...
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference - 4D Molecular Therapeutics ( NASDAQ:FDMT )
EMERYVILLE, Calif., Sept. 23, 2024 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics FDMT 4DMT or the Company ) ) ) , a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a poster ...
Why Is 4D Molecular Therapeutics Stock Plunging Today? - 4D Molecular Therapeutics ( NASDAQ:FDMT )
4D Molecular Therapeutics FDMT stock is trading lower on Thursday after the company released interim follow-up data from the Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design. Robust and durable treatment burden reduction was observed in all PRISM populations studied with the planned ...
Wall Street Analysts Think 4D Molecular Therapeutics ( FDMT ) Could Surge 225.1%: Read This Before Placing a Bet
The mean of analysts' price targets for 4D Molecular Therapeutics (FDMT) points to a 225.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4D Molecular Therapeutics ( FDMT ) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
4D Molecular Therapeutics (FDMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
4D Molecular Therapeutics, Inc. ( FDMT ) Reports Q2 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 12.50% and 99.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Carisma Therapeutics Inc. ( CARM ) Reports Q2 Loss, Tops Revenue Estimates
CARISMA THERAP (CARM) delivered earnings and revenue surprises of 25% and 151.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix ( OCUL ) Reports Q2 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -9.09% and 3.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board
EMERYVILLE, Calif., Aug. 05, 2024 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today strengthened the ...
Sage Therapeutics, Inc. ( SAGE ) Reports Q2 Loss, Tops Revenue Estimates
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -1.19% and 1.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
EXTON, PA., June 20, 2024, July 24, 2024 ( GLOBE NEWSWIRE ) -- The American Society of Retinal Specialists ( ASRS ) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking advancements in gene therapy for retinal disorders.
Why Is 4D Molecular Therapeutics Stock Trading Lower On Wednesday? - 4D Molecular Therapeutics ( NASDAQ:FDMT )
Wednesday, 4D Molecular Therapeutics, Inc.FDMT unveiled interim 24-week data from the Population Extension cohort of its PRISM Phase 2 Clinical Trial. The trial evaluates intravitreal 4D-150 in a broad wet AMD patient population.
4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
EMERYVILLE, Calif., July 17, 2024 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive ...
4D Molecular Therapeutics ( FDMT ) Moves 11.1% Higher: Will This Strength Last?
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ophthalmologists Favor Genentech's Vabysmo and Regeneron's Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
EXTON, PA., June 20, 2024, June 24, 2024 ( GLOBE NEWSWIRE ) -- The treatment landscape for Diabetic Macular Edema ( DME ) continues to evolve, with innovative therapies and emerging data significantly shaping prescribing patterns.
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
EMERYVILLE, Calif., June 08, 2024 ( GLOBE NEWSWIRE ) -- 4D Molecular Therapeutics ( Nasdaq: FDMT, 4DMT or the Company ) , a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today presented supplemental ...
